Hetero Biopharma launches RILAST - 1st Rituximab Biosimilar in Uzbekistan
Hetero Biopharma, the biologics wing of Hetero has recently launched RILAST- Rituximab in Uzbekistan, in alliance with our strategic business partner NF pharma. The launch event was hosted in Hotel…at Tashkent on 11th of December 2019.
The event was witnessed by the more than 25 Key Opinion Leaders(KOLs) from specialities of Haematology, Oncology. Session has created a new bay for the usage of Rituximab in treatment of multiple types of Leukaemia.
Dr Vikram Shetty (GM- Medico Marketing & Clinical Affairs) from Hetero Biopharma has presented the clinical applications of Rituximab and its clinical trials in Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukaemia.
Mr Vinod(Manager-Biologics Business) shared the overall vision of Hetero and Hetero Biopharma emphasizing the efforts of Hetero Biopharma in reaching every needy patient across the globe with our HBP’s corporate philosophy of REACH. He emphasized on our commitment of creating awareness on complex biosimilars across emerging markets.
Ms Ruslan Director, Ms Farangiz, Mr Rustam, Mr Abror and Ms Olesya from Sales and Marketing team of NF team accompanied by Mr Balaji and Mr Suneel from TheSay pharma organised the entire event in co-ordination with Marketing team of Hetero Biopharma headed by Dr A V Jayapala Reddy (Global Head – Biologics business) and Sharath Devalapelly (Asst.Manager-Marketing).
Delegates appreciated our efforts in making life saving complex drugs affordable, available and accessible to the needy patients across the globe.
KBB (Knowledge Beyond Borders), a global knowledge sharing initiative of Hetero Biopharma, firmly believe that sharing the knowledge on biosimilars to the medical fraternity in emerging markets will influence doctors to use Biosimilars to treat chronic ailments.